An ARGS-aggrecan assay for analysis in blood and synovial fluid  by Larsson, S. et al.
Osteoarthritis and Cartilage 22 (2014) 242e249An ARGS-aggrecan assay for analysis in blood and synovial ﬂuid
S. Larsson y*, L.S. Lohmander yzx, A. Struglics y
yDepartment of Orthopaedics, Clinical Sciences Lund, Lund University, Lund, Sweden
zResearch Unit for Musculoskeletal Function and Physiotherapy, University of Southern Denmark, Denmark
xDepartment of Orthopaedics and Traumatology, University of Southern Denmark, Denmarka r t i c l e i n f o
Article history:
Received 7 August 2013
Accepted 9 December 2013
Keywords:
Osteoarthritis
Aggrecan
Aggrecanase
Biomarkers
Blood
Synovial ﬂuid* Address correspondence and reprint requests to
Orthopaedics, Lund University, BMC C12, SE-221 84 Lu
4256; Fax: 46-46-211-3417.
E-mail addresses: staffan.larsson@med.lu.se (S.
med.lu.se (L.S. Lohmander), andre.struglics@med.lu.se
1063-4584/$ e see front matter  2013 Published by
http://dx.doi.org/10.1016/j.joca.2013.12.010s u m m a r y
Objective: To validate a modiﬁed ligand-binding assay for the detection of aggrecanase generated
aggrecan fragments with the ARGS neoepitope in synovial ﬂuid (SF) and blood, and to verify the identity
of aggrecan fragments found in blood.
Design: An enzyme-linked immunosorbent assay (ELISA) on the Meso Scale Discovery (MSD) platform
for detection of ARGS-aggrecan was validated, using a standard made from recombinant human
aggrecan. Matched samples of SF, serum, plasma, and urine were obtained from 36 subjects at different
time points after knee injury, and analysed for ARGS-aggrecan content. Aggrecan was puriﬁed from
serum and plasma pools and analysed by Western blot.
Results: The limits of quantiﬁcation for the ARGS-aggrecan assay was between 0.2 and 0.025 pmol ARGS/
ml, and the sensitivity of the assay was improved two-fold compared to when using a standard puriﬁed
from human donors. The ARGS concentrations were highest in SF (mean, range; 3.02, 0.36e30.22 pmol/
ml), 20 times lower in the blood samples (0.14, 0.055e0.28 pmol/ml serum and 0.13, 0.053e0.28 pmol/
ml plasma), and 80 times lower in urine (0.036, below detection e 0.087 pmol/ml). Serum-ARGS and
plasma-ARGS concentrations were similar, and correlated (rS ¼ 0.773, P < 0.001). SF concentration
correlated with serum concentrations (rS ¼ 0.420, P ¼ 0.011). In blood, we identiﬁed 129e138 kDa
aggrecan fragments containing the ARGS neoepitope.
Conclusions: This novel ARGS-aggrecan assay is highly sensitive and suited for analysis of SF and blood
samples. Both SF and blood contains ARGS-aggrecan, and ARGS concentrations in SF and serum are
correlated.
 2013 Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International.Introduction
Aggrecan, the major proteoglycan in articular cartilage, plays a
central role in cartilage compressibility and elasticity. In arthritis
and joint injury aggrecan is proteolysed mainly by matrix metal-
loproteases (MMPs) and aggrecanases (i.e., ADAMTS-4 and -5; a
disintegrin and metalloproteinase with thrombospondin motifs),
and the release of aggrecan fragments from cartilage is measurable
in synovial ﬂuid (SF)1e12, serum and urine4,10,13,14, and in cartilage
explant cultures7,15,16.
There are ﬁve known aggrecanase cleavage sites in aggrecan17,
and in terms of destructive loss of sulphated glycosaminoglycans
from the cartilage matrix, the most severe cleavage is at the
392Glu-393Ala bond within the aggrecan inter-globular domain: S. Larsson, Department of
nd, Sweden. Tel: 46-46-222-
Larsson), stefan.lohmander@
(A. Struglics).
Elsevier Ltd on behalf of Osteoart(IGD). This cleavage releases the N-terminal 393ARGS neoepitope
aggrecan fragments into SF.
ARGS-aggrecan fragments in SF have been analysed by enzyme-
linked immunosorbent assay (ELISA), electrochemiluminescence
(ELCL) andWestern blot. ARGS-fragments are detected in SF of knee
healthy subjects, with increased levels after joint injuries and in
joint diseases8,9,12,18,19. Quantiﬁcation of ARGS-aggrecan in SF is a
more sensitive tool to distinguish diseased and injured joints from
healthy than quantiﬁcation of total aggrecan8, or other aggrecanase
generated fragments12. Aggrecan fragments in SF have been char-
acterised by Western blot in SF20e22, but much less is known about
the structure of aggrecan fragments in plasma and serum23.
Well characterised and sensitive biomarker assays are essential
tools for analysis of patient samples and for our understanding of
cartilage degradation in arthritis and in joint injuries. We here
describe and characterise an ARGS-aggrecan ELCL assaywhich,with
modiﬁcations resulting in a two-fold increased sensitivity compared
to a previous version9, is capable of quantiﬁcation of the ARGS
neoepitope in SF, serum, and plasma. We also identify by Western
blot the presence of aggrecan fragments in serum and plasma.hritis Research Society International.
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Subjects and aggrecan preparations
All amino acid numberings are based on full-length human
aggrecan amino acid sequence starting with the N-terminal
1MTTL-24, NCBI accession number [Swiss-Prot: P16112].
Aggrecanwas puriﬁed fromvarious samples by caesium chloride
density gradient centrifugation under associative (A) and/or disso-
ciative (D) conditions as described22. A1D1-D3 fractions were pre-
pared fromahumanOAknee cartilagepool; characterisationof these
fractions was described22. Plasma-D1 and serum-D1 fractions were
from 27 ml of pooled samples of EDTA-plasma (n ¼ 59) or serum
(n ¼ 85) obtained at the local hospital from patients with unknown
disease history. An acute knee injury SF-D1poolwasmade bymixing
equal volumes of individual mini D1 preparations from SF of 40
subjects with acute knee injury. The SF samples of these patients
have been characterised and used in previous studies12,18,25.
From an ACL injury cohort (KANON-study; ISRCTN84752559,
http://www.controlled-trials.com) SF, serum, EDTA-plasma, and
urine from 36 patients at different times (0e5 years) after injury
were used for ARGS-aggrecan analysis (below), as were 14 SF
samples from a cross-sectional convenience cohort with data
available from the unmodiﬁed version of the ARGS ELCL assay
(using the previously described standard of ADAMTS-4 digested
aggrecan puriﬁed from human articular cartilage)9.
ARGS ELCL immunoassay
Samples were analysed for ARGS neoepitope concentration us-
ing a sandwich immunoassay with an ELCL technology on a Meso
Scale Discovery (MSD) platform26. The assay uses a capture anti-
body (AHP0022, Invitrogen) reactive against the globular domains
1 and 2 (G1 and G2) of human aggrecan, and a detection antibody
speciﬁc for the ARGS neoepitope (monoclonal antibody [MAb] OA-
1)7. It was modiﬁed from a previous version described for analysis
of SF9; modiﬁcations represent a change of standards (previously
utilizing puriﬁed aggrecan from human donors, now using re-
combinant human aggrecan), and in amendment of the deglyco-
sylation protocol for serum, plasma, and urine. The assay is
conducted as follows:
Pre-treatment of samples
Aliquots of centrifuged (3000 g, 10 min, 4C) SF (10 ml or 65 ml),
or serum, plasma and urine samples (65 ml) were deglycosylated for
3 h at 37C diluted 1:1.3 (ﬁnal volumes 13 ml or 84.5 ml, respectively)
in 50 mM Tris, 50 mM sodium acetate, 10 mM EDTA, 1 mM AEBSF,
10 mM NEM, pH 7.3, using Chondroitinase ABC (C2905, Sigmae
Aldrich), and keratanase (K2876, Sigma) with both enzymes at
0.4 mU per ml SF or 0.04 mU per ml serum, plasma, and urine. For
method evaluation, samples were then incrementally diluted
starting at undiluted after deglycosylation; for sample analysis, all
blood and urine samples were analysed without further dilution
after deglycosylation, and SF samples were analysed diluted to the
below speciﬁed limits of quantiﬁcation.
Standard
As ARGS standard, we used recombinant human aggrecan G1-
G2 (20VETS-CFRG675, 1220-PG, R&D Systems) digested with
ADAMTS-4 for complete conversion to G1-TEGE and ARGS-G2
fragments. Digestion was done at ADAMTS-4:aggrecan molar ra-
tio 1:428. We used a molecular weight of 74,000 g/mole for the
recombinant human aggrecan for conversion from gram to mole;
1 mol G1-G2 aggrecan was after ADAMTS-4-digestion assumed to
equal 1 mol ARGS-G2 (and 1 mol G1-TEGE) aggrecan. This standardwas used without deglycosylation. Standard curve range was for
method evaluation 5e0.002 pmol ARGS/ml, and for sample analysis
0.4e0.003 pmol ARGS/ml.
Assay protocol
High-bind 96-well microtitre plates (L15XB-3/L11XB-3, MSD)
were coated overnight at 4C with 25 ml/well of monoclonal anti-
human aggrecan (AHP0022, Invitrogen) diluted to 60 mg/ml in
PBST (0.01 M sodium phosphate, 0.138 M sodium chloride,
0.0027 M potassium chloride, 0.05% Tween 20; pH 7.4). After a
wash (all washes 3  400 ml PBST), plates were blocked (1 h, 22C,
plate shaker) with 150 ml/well of PBST containing 1% w/v BSA and
1% w/v non-fat dry milk. Plates were washed and incubated (2 h,
22C, plate shaker) with 25 ml/well of duplicates of standards or
samples diluted in PBST containing 1% w/v BSA. After a wash, plates
were incubated (2 h, 22C, plate shaker) with 25 ml/well of 1 mg/ml
biotinylated anti-ARGS (OA-17), and 1 mg/ml Sulfo-Tagged strepta-
vidin (R32AD-5, MSD) in PBST containing 1% w/v BSA. Plates were
emptied, 150 ml/well of 4 Read Buffer (R92TC-2, MSD) diluted 1:2
in ultrapure water was added and plates were read in an MSD
Sector Imager 6000. Sample concentrations of ARGS-aggrecanwere
calculated from the standard curve (four-parameter logistic) using
the MSD software. A control SF or serum sample was deglycosy-
lated and plated in duplicates on each plate and used for inter and
intra assay precision.
The limit of detection (LOD)27 was determined by the MSD
software on each analysed plate. The lower and upper limit of
quantiﬁcation (LLOQ and ULOQ) were calculated (mean values from
seven plates) by analysing at which lowest or highest concentration
the standard (and SF samples for the ULOQ) had dilution recoveries
between 80 and 120 percent, and coefﬁcient of variation (CV) be-
tween duplicates below 20 percent28: both standard and SF sam-
ples were used for the deﬁnition of the ULOQ due to their
differently shaped dilution curves at high concentrations (Fig. 3).
Thewell concentrations of standards (and SF samples for the ULOQ)
fulﬁlling these criteria were deﬁned as LLOQ and ULOQ. Samples
falling above the ULOQ were re-assayed at greater dilutions. Un-
diluted samples falling below LLOQ were imputed by being
assigned half the LLOQ as its measured concentration.
Extraction of aggrecan captured by the ARGS ELCL immunoassay
Coated and blocked MSD plates were incubated overnight with
96 wells (25 ml/well) each of the following deglycosylated samples:
SF pooled from 10 donors (ﬁnal dilution 1:3); serum pooled from 10
different donors (ﬁnal dilution 1:1.3); ADAMTS-4-digested A1D1
fractionated aggrecan from human articular cartilage (plated at
5 pmol aggrecan/ml); wells incubated with dilution buffer only.
Plates were washed (3  400 ml PBST), and remaining captured
proteins were extracted from the wells by incubation with 150 ml
per well of 4M guanidinium hydrochloride (2 h, 22C, plate shaker).
Well content was then pooled separately, and dialysed against
water containing inhibitors (0.4 mM PMSF,1 mMpepstatin A, 20 mM
iodoacetamide, 2 mM o-phenanthroline, and 0.8 mM EDTA). After
concentration on centrifugal ﬁlters (Centriprep Ultracel YM-10,
10,000 MWCO, Millipore), samples were given a second deglyco-
sylation to ensure optimal migration on SDS-PAGE (using 20 mU
chondroitinase ABC and keratanase, and 2 mU keratanase II per
sample regardless of actual aggrecan concentration), dried, dis-
solved in sample buffer and run on gels.
SDS-PAGE and Western blot analysis
Samples of cartilage A1D1 (with or without ADAMTS-4 diges-
tion), and SF-D1, serum-D1 and plasma-D1 samples, and in-well-
FFGV-CS1 (140-177)
ARGS -CS1 (129-138)
FFGV-CS2 (322)
ARGS-CS2 (310)
FFGV-CS1 (130-190)
ARGS-CS1 (130-160)
G1-G3 (>400)
FFGV-G3 (390)
G1-CS2 (340-370)
FFGV-CS2 (321)
G1-CS1 (210-245)250
150
100
75
50
37
FFGV ARGSFFGV ARGSG1 FFGV
Cartilage Synovial fluid Blood
P PS S
A B
SF S
Captured 
aggrecan
ARGS
BUA+
TS
4
250
150
100
75
50** * *
ARGS-CS2 
ARGS-CS1 
A+
TS
4
Fig. 1. Aggrecan fragments in cartilage, SF and blood detected by Western blot. (A) Large aggrecan fragments in cartilage are degraded into smaller fragments seen in SF, and this
process (arrows) continues in SF and blood. Aggrecan fragments were puriﬁed by: A1D1 preparation from a knee cartilage OA-pool, D1 preparations from an SF acute injury pool,
and serum and plasma pools. Puriﬁed aggrecan samples were deglycosylated and analysed (0.8e6 mg GAG per lane, 3e8% Triseacetate gels) by anti-ARGS, -FFGV and -G1 Western
blot. The Western blot immunosignal was blocked by immunisation peptides (not shown). Representative Western blot images from full sized blotted gels with aggrecan (molecular
weights in kDa) are shown. P, plasma. S, serum. (B) Captured and extracted aggrecan fragments from the wells of MSD plates coated with AHP0022 anti-G1/G2 antibody. Material
from 96 wells of each samples: SF, serum (S), ADAMTS-4-digested A1D1 aggrecan (A þ TS4), and dilution buffer (BU) as negative control e were extracted, pooled and analysed on
the anti-ARGS Western blot. The A þ TS4 sample was also run directly on the gel (0.75 mg GAG) as a positive control. False-positive immunobands are indicated by asterisks (*).
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tured and separated on NuPAGE SDS mini-gels (Invitrogen)21. Pro-
teins were electrophoretically transferred onto PVDFmembranes12.
Immunoreactions were done as described21, using G1 (anti-
ATEGQV-peptide sera, 1:5000), G1/G2 (AHP0022, Invitrogen, 2 mg/Fig. 2. The human recombinant G1-G2 peptide is completely degraded by aggreca-
nase. Recombinant human aggrecan G1-G2 peptide (20VETS-CFRG675, R&D #1220-PG)
was digested by ADAMTS-4 for 24 h at 37C. (A) Samples (0.18e0.31 mg/well) were run
on a 4e12% Bis-Tris SDS-PAGE gel as a digest (þ) or as a G1-G2 peptide (), and
aggrecan fragments were visualised by silver staining29 or by Western blot using G1/
G2 (AHP0022), G1, TEGE and ARGS-aggrecan antibodies. Representative silver stain
and Western blot images from full sized blotted gels with aggrecan (molecular masses
in kDa) are shown. *, silver stained false-positive none G1-G2 peptide bands below
37 kDa are marked. (B) Illustration of aggrecan G1-TEGE and ARGS-G2 fragments and
the recognition by the anti-G1/G2 and -ARGS antibodies. In the ARGS ELCL assay, anti-
G1/G2 is used as the capture antibody and anti-ARGS as the detection antibody.ml), ARGS (anti-ARGSVIL MAb OA-1, 7 mg/ml), FFGV (anti-
FFGVGGEEDC, AF28, Millipore, 0.5 mg/ml) and TEGE (anti-NITEGE
sera, 1:3000) antibodies together with secondary peroxidase con-
jugated antibodies of horse anti-mouse IgG (6.7e16.7 ng/ml) or
goat anti-rabbit IgG (10e13 ng/ml). The immunobands were
visualised using ECL (Pierce #80196) with exposure on ﬁlm.
Human recombinant G1-G2 aggrecanwith or without ADAMTS-
4 digestion was separated (without deglycosylation, 0.18e0.31 mg
per well) on 4e12% SDS-PAGE gels with aggrecan fragments
visualised by silver staining29, or by transfer and Western blot as
described above.
Statistics
We used the ShapiroeWilk test to assess normal distribution of
ARGS concentrations, Pearson’s correlation (r) for normally
distributed variables and Spearman’s rank order correlation (rS) for
data with skewed distribution. All tests were two-tailed and per-
formed using IBM SPSS Statistics version 20.0.0.
Results
Identiﬁcation of aggrecan fragments in puriﬁed blood samples
In the puriﬁed D1 samples of serum and plasma we identiﬁed
129e138 kDa aggrecanase generated ARGS- and 140e177 kDa
MMP-generated FFGV-aggrecan fragments [Fig. 1(A)]. Inhibition of
the immunosignal by the corresponding neo-peptides veriﬁed
speciﬁcity (not shown), and the C-terminals of these fragments
were estimated30 to be located within the chondroitin sulphate
(CS) region 1. Similar ARGS- and FFGV-fragments were also found in
puriﬁed SF-D1 samples, together with additional high molecular
weight (>250 kDa) ARGS-CS2 and FFGV-CS2 fragments [Fig. 1(A)],
as previously shown12,25. In comparison, cartilage contains high
molecular weight aggrecan G1- and FFGV-fragments [Fig. 1(A)]25,
but no ARGS-fragments21. No aggrecan fragments containing the
neoepitopes SELE or KEEE, or the G3 domain, were detected in the
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Fig. 3. Dilution curves of ARGS-aggrecan standard and samples. SF (A) and serum (B) concentrations from different subjects analysed in the ARGS ELCL assay plotted against the
dilution. Sample concentrations of ARGS-aggrecan at different dilutions were calculated against the standard curves using four-parameter logistics. Dilutions falling within the
range of detection as deﬁned by the Upper and Lower Limit Of Quantiﬁcation (ULOQ and LLOQ; described in the Methods section) were used for linearity of dilution calculations
(Table I), with mean values presented in the legends. Due to the different response to dilution between standard and SF above the ULOQ shown in panel A, the standard curve used
in the assay was as shown in panel B with eight standard points diluted incrementally 1:2 starting at 0.4 pmol/ml.
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which contain these fragments12.Identiﬁcation of aggrecan fragments captured by the AHP0022 anti-
G1/G2 antibody
In thematerial extracted from the anti-G1/G2 coatedMSD plates
in which ADAMTS-4 digested A1D1 aggrecan had been incubated,
we identiﬁed the same species (ARGS-CS1 and ARGS-CS2) as are
present in the original sample [Fig. 1(B)]. In the extracted material
from plates incubated with SF and serum, we identiﬁed ARGS-CS1
fragments of similar sizes as found in the D1-puriﬁed SF and blood
samples [Fig. 1(B)]. In wells incubated with SF, we saw no evidence
of large aggrecan fragments corresponding to the ARGS-CS2 frag-
ments identiﬁed in the SF-D1 fraction [Fig. 1(B)]. However, we
noted presence of ARGS-reactive bands of smaller sizes ranging
from 60 to 80 kDa. A 50 kDa ARGS-reactive band present in all
extracted samples, including the wells incubated with dilution
buffer only, is likely due to false reactivity by the anti-ARGS and/or
anti-IgG, possibly towards the albumin and milk proteins used to
block the MSD plates.ARGS ELCL development and validation
Characterisation of the ARGS standard
By silver stained SDS-PAGE gels and Western blots, we
conﬁrmed that the ADAMTS-4 digestion of the 105 kDa recombi-
nant human G1-G2 peptide (20VETS-CFRG675) resulted in two
fragments; the 62 kDa G1-TEGE392 and the 42e53 kDa 393ARGS-G2
(Fig. 2). No traces of undigested G1-G2 peptide were found after
digestion (Fig. 2), indicating that 1 mol of G1-G2 peptide was
converted to 1 mol of ARGS-G2 and 1 mol of G1-TEGE fragments.
We further veriﬁed that the capture antibody AHP0022 is reactive
with both ARGS-G2 and the G1-TEGE fragments of the digestedstandard (Fig. 2), suggesting that it recognises an amino acid
sequence present in both G1 and G2.Assay performance
Using the described ARGS standard gives a standard curve with
a working range from 5 pmol/ml to an average LOD of 0.010 pmol/
ml [Fig. 3(A)]. Applying the criteria for range of quantiﬁcation28 on
the assay based on seven individual experiments using standard
and SF, gave an LLOQ of 0.025 pmol/ml and a ULOQ of 0.20 pmol/ml.
At lower concentrations the CV of replicates and the recoveries
were outside the speciﬁed guidelines detailed in the Methods
section (not shown); at higher concentrations the dilution curves of
standard and SF were not parallel [Fig. 3(A)], resulting in a non-
linear response to dilution for the SF samples. Based on these
ﬁndings, an optimal standard curve for analysis of SF and serum
samples ranged between 0.40 and 0.0031 pmol/ml diluted in in-
crements of 1:2 [Fig. 3(B)]. Table I shows assay performance for
analysis of SF and serum using this standard curve within the
described range of detection.Comparison of the ARGS ELCL assay using old or new ARGS standard
In 14 SF samples with a wide range of ARGS concentrations, we
found a good correlation between analysis using old standard (with
aggrecan puriﬁed from human cartilage) and analysis using the
new standard (with recombinant human G1-G2 aggrecan) (Fig. 4).
There was, however, a shift in measured ARGS concentration using
the different standards with a mean ratio of new:old being 0.15 (SD
0.035). Importantly this ratio was the same independent of ARGS
concentration (not shown). The LLOQ using the old standard was
0.30 pmol/ml9, which with conversion (multiplied by 0.15) would
correspond to 0.045 pmol/ml as if measured with the new stan-
dard. The 0.025 pmol/ml LLOQ using the new standard (Table I),
thus represent a two-fold increased sensitivity compared to the
0.045 pmol/ml using the old standard.
Table I
Technical performance of the ARGS ELCL. The ARGS assay was validated using SF and
serum. Assay range of LOD, and lower limit of quantiﬁcation (LLOQ) were calculated
using standards, and the ULOQ using standards and SF. Dilution recovery was con-
ducted using SF (n¼ 9) and serum (n¼ 6) from selected subjects, and was calculated
from dilutions falling within the LLOQ and ULOQ range. For SF this ranged between
1:23 and 1:632 dilution and for serum 1:1.3 to 1:5.2. Dilution linearity is expressed
as follows: 100 (concentration at a speciﬁc dilution divided by the mean con-
centration of all dilutions within the LLOQ and ULOQ span). Spiking recovery was
performed by adding standard calibrator at different concentration to 10 (SF) or 5
(serum) randomly selected samples and expressed as follows: 100 ((measured
concentration of a sample spiked with a speciﬁc amount of standard) divided by
(measured concentration of the un-spiked sample þ the concentration of the added
amount of standard)). Intra and inter assay CV was calculated from an SF-control
sample (intra n ¼ 14 wells, inter n ¼ 19 plates) and a serum-control sample (intra
n ¼ 5 wells, inter n ¼ 18 plates)
Assay range, pmol/ml Recovery, % (range) CV, %
LOD LLOQ ULOQ Dilution Spiking Intra Inter
SF 0.010 0.025 0.200 100 (90e110) 94 (86e107) 4.2 13.7
Serum 0.010 0.025 0.200* 100 (83e117) 89 (77e110) 2.9 22.7
* Determined using standard and SF; serum concentration were below ULOQ.
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0e5 years after ACL injury
All SF, serum, and plasma samples had ARGS concentrations
above the LLOQ. However, 12 of 36 urine samples had concentra-
tions below LLOQ, therefore their concentrations were imputed
with half the LLOQ (0.0125 pmol/ml) (Fig. 5, empty circles).
The ARGS-aggrecan concentrations in the different body ﬂuids
was highest, and with the greatest range, in SF (mean, range; 3.02,
0.36e30.22 pmol/ml), were 20 times lower in the blood samples
(0.14, 0.055e0.28 pmol/ml serum and 0.13, 0.053e0.28 pmol/ml
plasma), and 80 times lower in urine (0.036, <0.025e0.087 pmol/
ml, or 2.39, 0.50e5.57 pmol/mmol creatinine) (Fig. 5).
Serum, plasma and SF concentrations of ARGS-aggrecanwere all
correlated, with the highest similarity and strongest correlation
between serum and plasma (rS ¼ 0.773, P < 0.001; Fig. 5). Urinary
concentrations of ARGS did not correlate with concentrations in SF,
serum or plasma (Fig. 5).SF-ARGS with Old standard (pmol/ml)
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Fig. 4. A scatter plot of 14 SF samples analysed in the ARGS ELCL assay. Analysis using
old standard prepared from aggrecan extracted from human cartilage (Old SF-ARGS; X-
axis) against analysis using the new standard prepared from human recombinant G1-
G2 aggrecan (New SF-ARGS; Y-axis). Pearson’s correlation coefﬁcient (r), a regression
line (solid), and a line of equality (dashed) are indicated.Discussion
We here provide a detailed description and validation of an
assay for the detection of aggrecanase generated aggrecan frag-
ments with the ARGS neoepitope. Using deﬁned criteria for eval-
uation of ligand-binding assays28, we show that this assay is well
suited to analyse ARGS-aggrecan concentrations in human SF,
serum and plasma.
The present assay was developed based on the principle of a
sandwich ELISA that relied on a capture antibody directed at the
keratan sulphate chains in combination with the OA-1 anti-ARGS
detection antibody7,8. We have since described a second generation
ARGS-aggrecan quantiﬁcation assay when changing to the now
used AHP0022 capture antibody (reactive with the G1 and G2 do-
mains of aggrecan9, and Fig. 2) in combination with the OA-1 ARGS
antibody for detection, as we simultaneously made the transition
from a traditional ELISA format to the multiplex ELCL format on the
MSD platform9,31. In both these ARGS-aggrecan assays, and in an
ARGS ELISA developed at Pﬁzer11, ARGS standards were prepared
by ADAMTS-4-digestion of aggrecan puriﬁed from articular carti-
lage donated from humans at the time of knee arthroplasty. We
have here shown how the use of standard prepared by ADAMTS-4-
digestion of a commercially available recombinant human aggrecan
fragment has resulted in a two-fold increased sensitivity in the G1/
G2 capture/ARGS detection MSD assay, allowing for quantiﬁcation
also in serum, plasma and, to some degree, in urine.
Using recombinant human aggrecan in the standard preparation
instead of aggrecan puriﬁed from human cartilage provides further
beneﬁts in the present assay. Firstly, it improves precision in the
calculation of molar content of the ARGS neoepitope of the stan-
dard. With a known amino acid sequence of the recombinant
protein, it is not necessary to make assumptions of molecular
weight of the core protein and the glycosaminoglycans, of the de-
gree in glycosylation, or of the proportion and size of fragments not
being of full-length in the puriﬁed sample, assumptions necessary
when using aggrecan puriﬁed from human donors.
Secondly, using recombinant protein increases repeatability: it
is now possible to reproducibly generate ARGS-standard using
commercially available products. When using aggrecan puriﬁed
from human donors, we found batch variation in standards to be
unacceptably high (not shown), probably due to between-donor
variation in the proportions of differently sized aggrecan frag-
ments and in the degree of glycosylation, both of which would
inﬂuence the accuracy of the estimated molecular weight used for
calculation of the standard.
Thirdly, it is also possible, as we show in Fig. 2, to control that
the enzymatic degradation of the recombinant aggrecan has been
complete, so that the assumption of 1 mol recombinant G1-G2
aggrecan being converted to 1 mol G1-TEGE and 1 mol ARGS-G2
can be made.
Others have used the same recombinant protein digested by
ADAMTS-4 in the standard preparation for a recently developed
ARGS-aggrecan ELISA10. They, however, choose to express their
results from the quantiﬁcation as weight (ng or pg) per ml body
ﬂuid or culture media. With the size and weight of aggrecan frag-
ments varying substantially within and between samples, and the
size and weight of the digested recombinant aggrecan standard
being constant and not reﬂecting the sizes and weights of analysed
fragments, we ﬁnd that expressing the quantity in mole ARGS per
volume is more accurate since molar content of any sample or
standard is independent of the sizes and weights of the aggrecan
fragments.
A calibration of the new standard against the old standard
showed a seven-fold reduction of concentration values. This
reduction in absolute values was equal regardless of ARGS
0.1
1 10 100
0.1
1 10 100
1
10
0.1 0.1
1
10
se
ru
m
-A
R
G
S
(pm
ol/
ml
)
pl
as
m
a-
AR
G
S
(pm
ol/
ml
)
u
rin
e-
AR
G
S
(pm
ol/
mm
ol 
cre
ati
nin
e)
SF-ARGS
(pmol/ml)
serum-ARGS
(pmol/ml)
plasma-ARGS
(pmol/ml)
rS = 0.420, P = 0.011
rS = 0.386, P = 0.020
rS = 0.157, P = 0.361
rS = 0.773, P < 0.001
rS = 0.194, P = 0.257 rS = 0.105, P = 0.544
Fig. 5. A rug-plot of bivariate scatters of ARGS-aggrecan concentrations in different body ﬂuids. Samples were SF, serum, plasma, and urine from 36 subjects (six subjects per time
point) at different times (0e5 years) after ACL injury. ARGS-aggrecan concentrations in the samples were measured using the ARGS ELCL assay. Concentrations in urine are given
corrected for urinary creatinine. Filled circles are concentrations measured within the detection limits of the ARGS ELCL assay. Open circles are urinary ARGS concentration below
the assay Lower Limit Of Quantiﬁcation (LLOQ; 0.025 pmol/ml) that were imputed to half the LLOQ value. Linear regression lines (solid) with 95% conﬁdence intervals (long dashed)
are indicted in each scatter plot. In the rug-plot, each bivariate scatter plot shares information of one variate with the adjacent plot, illustrated by interconnecting rug fringes
showing the marginal distribution of the shared variate. To facilitate interpretation, horizontal and vertical lines (short dashed) interconnect ARGS concentrations in different
bivariate combinations of ﬂuids in one subject. All scales are logarithmic and reﬂect the range of ARGS concentrations in each ﬂuid. Spearman’s rank order correlation (rS) was used
based on skewed distribution of a majority of the variables.
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tween absolute values of ARGS-aggrecan using the two standards
(Fig. 4). Thus, the relative differences in ARGS concentration be-
tween samples were the same regardless of which standard was
used.
Using the new standard, we deﬁned upper and lower limits of
quantiﬁcation for the assay. In deciding the ULOQ, the use of dilu-
tion curves of SF was critical, since the shoulders of these curves are
clearly lower and not parallel to the standard curve above the
speciﬁed ULOQ [Fig. 3(A)], resulting in poor dilution recovery above
this point. The most probable cause for this is a saturation of the
capture antibody by aggrecan fragments not carrying the ARGS
neoepitope, and that the proportion of those fragments are higher
in the samples compared to the standard. This type of saturation
was also noted by Chockalingam and colleagues who found that
their similar sandwich ARGS ELISA (using the same capture anti-
body) was saturated above 5 mg of proteoglycan per well (personal
communication and11). However, as long as the dilution curve of
SFs (or sera) are parallel to the standard curve, we assume that the
detected fragments in the samples have the same reaction to
dilution as the detected fragments in the standard.Within the LLOQand ULOQ we ﬁnd dilution and spiking recoveries that lie well
within the recommended 80e120% (Table I). Based on this infor-
mation we recommend a standard curve ranging from 0.4 to
0.003 pmol ARGS per ml [Fig. 3(B)], for all types of body ﬂuids. To
our knowledge, the present assay is the only one of the published
ligand-binding assays for quantiﬁcation of ARGS-aggrecan7e11,14
that specify quantiﬁcation limits according to deﬁned criteria for
bioanalytical method validation.
We also provide novel characterization on aggrecan fragments
present in blood that are potentially detected by this ARGS-aggrecan
assay. In blood puriﬁed by density gradient centrifugation we ﬁnd
the ARGS-C1 (and FFGV-CS1) that also are present in SF. However,
we do not ﬁnd the larger ARGS-CS2 (and FFGV-CS2) that are present
in SF [Fig. 1(A)]. All of these fragments identiﬁed in density gradient
fractionated samples of blood and SF includes the G2-domain, and
are thus potentially captured by the anti-G1/G2 antibody. Impor-
tantly, we show that (in similarity with the KS/OA-1 ELISA8) the
ARGS ELCL assay has the capability to capture both the high mo-
lecular weight ARGS-CS2 and the low molecular weight ARGS-CS1
fragments, as is evident from the in vitro digested A1D1 aggrecan
extracted fromwells [Fig.1(B)]. However, in captured aggrecan from
S. Larsson et al. / Osteoarthritis and Cartilage 22 (2014) 242e249248wells incubated with SF, we found that the large molecular weight
ARGS-CS2 fragments present in puriﬁed SF samples appears as not
being captured, or at least captured to a lesser degree than the
smaller ARGS-CS1 fragments [Fig. 1(B)]. This apparent difference in
species composition can derive from differences in the puriﬁcation
steps (with one sample puriﬁed based on the net negative charge of
the proteoglycan interacting with caesium ions, and one sample
puriﬁed by antibodyeantigen interaction).
Through proteolytic degradation, aggrecan fragments are
released from the cartilage into the joint ﬂuid where we have
identiﬁed ARGS-CS1 and ARGS-CS2 fragments [Fig. 1(A)]18,21,22.
With no ARGS-aggrecan being found in the cartilage21,22, we assume
that these fragments are produced by recent aggrecanase activity.
This assumption can however not be made for the FFGV-fragments
found in SF, since we repeatedly in different samples have seen
presence of FFGV-CS2 fragment in cartilage [Fig. 1(A)]21,25. Further,
we assume that themajority of aggrecan fragments found in SF have
originated from the joint of study. Aggrecan fragments residing in
blood or urine, however, can have originated from any of the joints
or from the intervertebral discs of the body.
Using matched SF, serum, plasma and urine samples from a
small set of patients at different time points after knee injury we
show that levels correlate between different ﬂuids, and that there is
a good correlation and similarity between serum and plasma
samples. We especially note that there is a moderate correlation
(rS ¼ 0.420) between ARGS-aggrecan concentrations in SF and
serum (Fig. 5). We ﬁnd this interesting, since we previously have
shown SF levels of ARGS, or change in those levels over time, to be
associated with pathology or progression of knee OA9,31, and that
serum is a much easier ﬂuid to obtain in a clinical perspective.
Molecules such as hyaluronic acid are cleared from the blood
stream by the liver within minutes32, whereas collagen crosslinks
are not metabolised by the liver and kidney and found in urine33,34.
We here ﬁnd that the absolute concentrations of ARGS-aggrecan in
urine (before adjustment for urinary creatinine) are lower than
plasma or serum concentrations, and that although detectable,
these concentrations are close to, or below, the LLOQ of the ARGS
ELCL assay. The much lower urinary concentrations, and the lack of
correlation between ARGS in urine and the other ﬂuids, indicates
that measurement of ARGS in urine has less potential as a
biomarker with links to pathology. This is corroborated by another
ARGS ELISA that appears to be sensitive enough for these small
concentrations, where no between-group differences for different
stages of OA were found10.
In summary, the ARGS ELCL assay here presented is a highly
sensitive assay for measuring aggrecan ARGS-fragments generated
by aggrecanase activity. We have validated it for analysis of both SF
and serum samples, and in a small set of samples show how ARGS
concentrations correlate between different body ﬂuids. Finally we
show novel characterization on the identity of aggrecanase gener-
ated ARGS-aggrecan as well as MMP-generated FFGV-aggrecan in
human blood samples.
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